HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Justin Nowell Marjan Jahangiri Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nowell, J. Articles by Jahangiri, M. Search for Related Content PubMed PubMed Citation Articles by Nowell, J. Articles by Jahangiri, M. Related Collections Cardiac - pharmacology Valve disease

Eur J Cardiothorac Surg 2007;31:578-585. doi:10.1016/j.ejcts.2006.12.017
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Reviews

Antithrombotic therapy following bioprosthetic aortic valve replacement

Department of Cardiothoracic Surgery and Neurosciences, St. George's Hospital, University of London, UK

Received 19 July 2006; received in revised form 6 December 2006; accepted 14 December 2006.

^_* Corresponding author. Address: Department of Cardiothoracic Surgery, St. George's Hospital, Blackshaw Road, London, SW17 0QT, UK. Tel.: +44 208 725 3565; fax: +44 208 725 2049. (Email: marjan.jahangiri{at}stgeorges.nhs.uk).

The life expectancy of the general population is increasing. This has meant that more elderly patients are requiring aortic valve replacement (AVR). The choice of valve replacement and its durability are important. Bioprosthetic (tissue) heart valves were introduced into clinical use in the 1960s and were developed primarily to reduce the complications associated with thromboembolism (TE) and the need for lifelong oral anticoagulation, due to their low thrombogenicity compared to mechanical prostheses. This makes them suitable for use in elderly patients (aged > 65 years) and in others where the risks of anticoagulation are higher or anticoagulation is contraindicated. There is thought to be a higher risk of TE for up to 90 days following bioprosthetic AVR. Guidelines for the management of patients with valvular heart disease published by the American College of Cardiology (ACC)/American Heart Association (AHA), the American College of Chest Physicians (ACCP) and the European Society of Cardiology (ESC) all recommend the use of an anticoagulation regimen for the first 3 months following bioprosthetic AVR. However, there is division of opinion and practice, despite these recommendations, and more recent studies have not supported the evidence for these guidelines. In this article, we review the literature on the use of anticoagulation in the first 90 days following bioprosthetic AVR.

Key Words: Bioprosthesis • Anticoagulation • Aortic valve

This article has been cited by other articles:

				J. I. Aramendi and C.-A. Mestres Antithrombotic therapy after bioprosthetic aortic valve replacement Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 529 - 530. [Full Text] [PDF]

				A. Colli, J.-P. Verhoye, R. Heijmen, J. T. Strauch, J. A.J. Hyde, D. Pagano, M. Antunes, H. Koertke, S. K. Ohri, D. H. L. Bail, et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 531 - 536. [Abstract] [Full Text] [PDF]

				J. Nowell and M. Jahangiri Antiplatelet therapy after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 945 - 945. [Full Text] [PDF]

				J. Dunning Laws, Guidelines and professional choice Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 571 - 572. [Full Text] [PDF]